Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $12M (up 78.7% year over year) with net income of −$637,000.
Q3 2025 key financials · XBRL
- Revenue
- $12M
- +78.7% YoY · +29.1% QoQ
- Net income
- −$637,000
- +88.9% YoY · +79.8% QoQ
- Operating margin
- -1.5%
- EPS (diluted)
- −$0.02
- +88.9% YoY · +83.3% QoQ
Source: XBRL data from the FENNEC PHARMACEUTICALS INC. (FENC) Q3 2025 10-Q on SEC EDGAR. USD.
FENNEC PHARMACEUTICALS INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $12.462M, up $5.488M YoY from $6.974M, driven by PEDMARK sales and $70K Norgine royalties
- Operating margin (1.5%) vs (74.6%) YoY; net loss $638K vs $5.735M
- Only product PEDMARK sales $12.462M, up $5.488M YoY; no segment comparison disclosed
- Cash $21.947M vs $26.634M at December 31; nine-month operating cash flow $(6.511)M vs $28.454M
- Near-term headwinds: tariff uncertainty, lower cash balances, additional financing needs, and uncertain capital requirements
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 rather than comparative 10-Q risk disclosures
- Director trading-plan risk: disposition of up to 109,184 shares through June 9, 2026
- No additional director or officer reported adoption, modification, or termination of trading arrangements
- Regulatory disclosure: press release furnished under Exchange Act Section 18 and not incorporated by reference
- No liquidity, debt, currency, operational, competitive, or market risks disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FENNEC PHARMACEUTICALS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.